Top Suppliers:I want be here


2241732-30-7

2241732-30-7 structure
2241732-30-7 structure

Name BTK-030
Description BTK-030 is a novel BTK inhibitor.
Related Catalog
Target

IC50: Bruton kinase (BTK)[1]

In Vivo BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33[1]. Animal Model: DBA/1J mice injected with collagen as a CIA model[1] Dosage: 30 mg/kg Administration: oral gavage; 21 days; once daily Result: Decreased arthritis scores significantly when it compares to control group.
References

[1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525

Molecular Formula C25H23N5O3
Molecular Weight 441.491
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.